Business Wire

VERIMATRIX

9.9.2019 18:36:05 CEST | Business Wire | Press release

Share
Swift Media Reinvests in Verimatrix with VCAS Ultra Upgrade and Expansion

Regulatory News:

IBC 2019 (#5.A59) Verimatrix (Paris:VMX), a global provider of security and business intelligence solutions that protect content, devices, applications and communications, today announced that its customer, Swift Media, has evolved its existing Verimatrix Video Content Authority System (VCAS™) to a more efficient cloud infrastructure that better supports new business models and 4K/UHD video services. The expansion includes upgrading to the next-generation VCAS Ultra solution and adding multi-DRM support.

Swift Media delivers world-class content, data-driven advertising and site-specific services to guest accommodation, workforce communities and other large captive audience environments. The company, which specifically targets the “away from home” audience, decided to upgrade its existing security framework to better support its scale and reach as it enters new verticals in the hospitality space and introduces enhanced business models based on advertising.

“Our proven, industry-grade communications and entertainment solutions have made us the largest and most trusted supplier in the resources sector, and it is critical that we maintain our long-standing reputation as we grow and tap into more markets,” said Swift Media’s CTO Matt Strack. “Swift Media has entrusted Verimatrix to support its service offerings for many years, originally initial supporting our IPTV offering, then moving into OTT and now UHD. We are very pleased to continue to modernize our business with such reliable support.”

The VCAS Ultra deployment makes it possible for Swift Media to manage disparate systems from a centralized cloud. It also enables UHD compliance capabilities and additional support for browsers and streaming devices it couldn’t reach previously. The addition of Verimatrix Multi-DRM means that Swift Media can provide a transparent consumption experience using cross-DRM domain management while comprehensively protecting valuable services.

“It is thrilling to see another one of our customers come such a long way since its original VCAS deployment, harnessing all that the next-generation video landscape has to offer,” commented Verimatrix COO Steve Oetegenn. “This deployment takes Swift Media’s original VCAS multi-network architecture and completely transforms the way it harmonizes rights management in a more flexible and mature way.”

About Swift Media
Swift Media delivers world-class content, customized communications, and targeted advertising to captivated audiences across Swift-owned networks. Founded in 2008 and listed on the Australian Stock Exchange under the ticker SW1, Swift Media was judged Australia’s fastest growing media company by Deloitte in 2018. For more information, visit www.swiftmedia.com.au

About Verimatrix
Verimatrix (Euronext Paris: VMX) is a global provider of security and business intelligence solutions that protect content, devices, applications and communications across multiple markets. Many of the world’s largest service providers and leading innovators trust Verimatrix to protect systems that people depend on every day for mobile apps, entertainment, banking, healthcare, communications and transportation. Verimatrix offers easy-to-use software solutions, cloud services and silicon IP that provide unparalleled security and business intelligence. Proud to empower and protect its customers for more than two decades, Verimatrix serves IoT software developers, device makers, semiconductor manufacturers, service providers and content distributors. For more information, visit www.verimatrix.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/VerimatrixInc/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release

In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release

IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye